[EN] NOVEL CYSTOBACTAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE CYSTOBACTAMIDES
申请人:HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH
公开号:WO2019038405A1
公开(公告)日:2019-02-28
The present invention relates to novel derivatives of cystobactamides of formula (lb) and the use thereof for the treatment or prophylaxis of bacterial infections.
本发明涉及公式(lb)的半胱菌肽的新颖衍生物及其用于治疗或预防细菌感染的用途。
Cystobactamide derivatives
申请人:HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
公开号:US11034648B2
公开(公告)日:2021-06-15
The present invention relates to novel derivatives of cystobactamides of formula (Ib) and the use thereof for the treatment or prophylaxis of bacterial infections.
本发明涉及式(Ib)胱内酰胺的新型衍生物及其在治疗或预防细菌感染中的应用。
New, Axially Chiral, Bimetallic Catalysts for Asymmetric Alkylation of Aldehydes with Diethylzinc
Axially chiral bis(salicylidene)ethylenediamine (H(2)salen)-type ligands 3 (cf: Schemes 1 and 3) are efficient ligands for the enantioselective addition of diethylzinc to aldehydes. There is ample evidence that an active bimetallic catalyst forms an effective chiral pocket (see Fig.2); of a series of first-row transition-metal complexes with these ligands, the most stereoselective were the Co-II complexes (see Fig. I). Best ee values as well as the fastest rates (see Tables 2 and 3) were obtained with these Co-II complexes when an EtO substituent was present at C(3) of the salicylaldehyde residues of ligand 3 (R-1 = EtO), Le., complex [Co-II(3'h)] produced up to 93% ee with aromatic aldehydes and 78% ee for aliphatic aldehydes (see Table 4).
NOVEL CYSTOBACTAMIDE DERIVATIVES
申请人:Helmholtz-Zentrum für Infektionsforschung GmbH
公开号:EP3672937A1
公开(公告)日:2020-07-01
Enantioselective Cobalt-Catalyzed Preparation of Trifluoromethyl-Substituted Cyclopropanes
作者:Bill Morandi、Brian Mariampillai、Erick M. Carreira
DOI:10.1002/anie.201004269
日期:2011.2.1
Easy access on water: A cobalt‐catalyzed asymmetric preparation of trifluoromethylcyclopropanes has been developed that yields high enantioselectivities with a broad range of styrene substrates (see scheme). The reaction presents a new access to enantioenriched CF3‐containing building blocks.